Illumina (NASDAQ:ILMN) Updates FY 2020 After-Hours Earnings Guidance

Illumina (NASDAQ:ILMN) issued an update on its FY 2020
After-Hours earnings guidance on Monday morning. The company provided earnings per share guidance of 6.80-7.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.06. The company issued revenue guidance of $3.86-3.93 billion, compared to the consensus revenue estimate of $3.96 billion.Illumina also updated its FY 2019
After-Hours guidance to EPS.

Shares of Illumina stock opened at $324.46 on Tuesday. Illumina has a 1 year low of $263.30 and a 1 year high of $380.76. The firm has a market cap of $49.32 billion, a PE ratio of 56.72, a PEG ratio of 2.26 and a beta of 1.05. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.82 and a quick ratio of 6.15. The company has a 50 day simple moving average of $326.73 and a two-hundred day simple moving average of $310.23.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 24th. The life sciences company reported $1.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.53. Illumina had a net margin of 28.14% and a return on equity of 22.05%. The business had revenue of $907.00 million during the quarter, compared to analyst estimates of $872.65 million. During the same period in the previous year, the business posted $1.52 earnings per share. Illumina’s revenue for the quarter was up 6.3% on a year-over-year basis. As a group, research analysts anticipate that Illumina will post 6.45 earnings per share for the current year.

Several equities research analysts have issued reports on ILMN shares. Wells Fargo & Co started coverage on shares of Illumina in a research report on Tuesday, January 7th. They set an underweight rating and a $300.00 target price for the company. Wolfe Research set a $380.00 target price on shares of Illumina and gave the company a buy rating in a research report on Friday, October 25th. Piper Jaffray Companies dropped their target price on shares of Illumina from $348.00 to $341.00 and set an overweight rating for the company in a research report on Friday, October 25th. Stifel Nicolaus started coverage on shares of Illumina in a research report on Thursday, November 14th. They set a buy rating and a $345.00 target price for the company. Finally, UBS Group upgraded shares of Illumina from a neutral rating to a buy rating and set a $355.00 target price for the company in a research report on Friday, January 3rd. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Illumina presently has an average rating of Buy and an average price target of $340.69.

In related news, SVP Charles Dadswell sold 193 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $297.28, for a total value of $57,375.04. Following the transaction, the senior vice president now owns 5,069 shares in the company, valued at approximately $1,506,912.32. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Susan H. Tousi sold 200 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $325.00, for a total transaction of $65,000.00. Following the completion of the transaction, the senior vice president now owns 38,465 shares in the company, valued at approximately $12,501,125. The disclosure for this sale can be found here. Insiders have sold 3,920 shares of company stock worth $1,262,212 over the last three months. Insiders own 0.38% of the company’s stock.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Read More: Is a Roth IRA right for you?

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.